The first 60 days: HPV-independent vulvar squamous cell carcinoma (p53-mutant)
HPV-independent vulvar cancer is the commoner type of vulvar squamous cell cancer, arising in older women from the chronic skin condition lichen sclerosus rather than from HPV, and marked by faults in the p53 gene. It recurs locally far more often than the HPV type, so treatment centres on complete surgical removal, control of the surrounding skin disease and long follow-up. Below, week by week, is what OnCo's record of HPV-independent vulvar squamous cell carcinoma (p53-mutant) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Precursor (differentiated VIN) and lichen sclerosus, Early stage.
- SurgeonNamed in the standard of care for: Precursor (differentiated VIN) and lichen sclerosus, Early stage, Locally advanced disease.
- Medical oncologistNamed in the standard of care for: Early stage, Locally advanced disease, Recurrent or metastatic disease.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Early stage, Locally advanced disease.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Wide local excision with attention to margins, sentinel node biopsy or inguinofemoral lymphadenectomy by the GROINSS-V criteria; adjuvant radiotherapy for close margins or positive nodes.
Cisplatin chemoradiotherapy with surgery for residual disease; responses are less complete than in p16-positive tumours.
Excision of differentiated VIN; long-term potent topical corticosteroids for lichen sclerosus; low threshold for biopsy of new lesions.
Carboplatin and paclitaxel with or without bevacizumab; pembrolizumab for PD-L1-positive tumours; trials of pembrolizumab with lenvatinib and of cadonilimab.
Lifelong surveillance of the vulvar skin because new tumours arise in the lichen sclerosus field years later.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example p53 immunohistochemistry, p16 immunohistochemistry, TP53 sequencing where immunohistochemistry is equivocal, NOTCH1 and HRAS mutations, Margin status and presence of differentiated VIN or lichen sclerosus at the margin), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Differentiated vulvar intraepithelial neoplasia, HPV-independent p53-mutant vulvar squamous cell carcinoma, HPV-independent p53 wild-type vulvar squamous cell carcinoma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Precursor (differentiated VIN) and lichen sclerosus
- For my situation (precursor (differentiated vin) and lichen sclerosus), which of the standard options do you recommend and why?Guideline options include: Excision of differentiated VIN; long-term potent topical corticosteroids for lichen sclerosus; low threshold for biopsy of new lesions.
Early stage
- For my situation (early stage), which of the standard options do you recommend and why?Guideline options include: Wide local excision with attention to margins, sentinel node biopsy or inguinofemoral lymphadenectomy by the GROINSS-V criteria; adjuvant radiotherapy for close margins or positive nodes.
Locally advanced disease
- For my situation (locally advanced disease), which of the standard options do you recommend and why?Guideline options include: Cisplatin chemoradiotherapy with surgery for residual disease; responses are less complete than in p16-positive tumours.
- Am I a candidate for Cisplatin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Recurrent or metastatic disease
- For my situation (recurrent or metastatic disease), which of the standard options do you recommend and why?Guideline options include: Carboplatin and paclitaxel with or without bevacizumab; pembrolizumab for PD-L1-positive tumours; trials of pembrolizumab with lenvatinib and of cadonilimab.
- Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Bevacizumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge and AK104 for Recurrent or Metastatic Vulvar Cancer apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Follow-up
- For my situation (follow-up), which of the standard options do you recommend and why?Guideline options include: Lifelong surveillance of the vulvar skin because new tumours arise in the lichen sclerosus field years later.
Any stage
- Are there clinical trials I could join, for example of Pembrolizumab, Cemiplimab, Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge, AK104 for Recurrent or Metastatic Vulvar Cancer?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Differentiated VIN is hard to recognise and is often diagnosed only next to an invasive cancer”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Whether wider margins or adjuvant radiotherapy prevent the frequent local recurrences has not been tested prospectively”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- AK104 for Recurrent or Metastatic Vulvar CancerPhase 2 · recruiting · NCT05932212A Multicenter, Open-label, Phase II Study of AK104 in the Treatment of Recurrent or Metastatic Vulvar Cancer
- Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative SurgePhase 2 · recruiting · NCT05903833Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- HPV-independent vulvar squamous cell carcinoma (p53-mutant): the full pageHPV-independent vulvar cancer is the commoner type of vulvar squamous cell cancer, arising in older women from the chronic skin condition lichen sclerosus rather than from HPV, and marked by faults in the p53 gene. It recurs locally far more often than the HPV type, so treatment centres on complete surgical removal, control of the surrounding skin disease and long follow-up.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Combined positive score (CPS): A PD-L1 score that counts stained tumour cells and immune cells together.
- HPV-positive (p16) head and neck cancer: Throat cancers caused by the human papillomavirus, identified by a p16 stain.
- Lymphadenectomy (lymph node dissection): Surgically removing the lymph nodes that drain a tumour, both to stage the cancer and to clear any spread.
- Chemoradiation (chemoradiotherapy, CRT): Radiotherapy given at the same time as chemotherapy, which sensitises the cancer to radiation.
Every term links to the glossary.